1983
Founded In 1983
Virchow Labs established for manufacture of Sulfamethoxazole API.
2001
In 2001
Virchow Biotech incorporated for manufacture of recombinant and classical biologicals in collaboration with US based scientist group.
2002
In 2002
Covalent Labs incorporated for manufacture of oral Cephalosporin APIs.
2003
In 2003
First US FDA approval in Group for Virchow Labs.
2004
In 2004
Acquisition of Andhra Organics in Vizag. 100 acre site with adequate facilities for future expansions.
2007
In 2007
Started manufacture of GCLE, a key Cephalosporin intermediate at Virchow Petrochemicals.
2009
In 2009
Started marketing of formulations in international markets
2011
In 2011
Group revenues cross Rs 1,000 crore.
2012
In 2012
Foray into branded formulation marketing in India.
In 2012
Started manufacture of Sterile Cephalosporins at Covalent.
2014
IN 2014
Group revenues cross Rs 2,000 crore.
2017
In 2017
Group revenues cross 3000 Crores ($500 Million).